-$4.81 Earnings Per Share Expected for argenx SE (NASDAQ:ARGX) This Quarter

Analysts predict that argenx SE (NASDAQ:ARGXGet Rating) will post earnings per share (EPS) of ($4.81) for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for argenx’s earnings, with estimates ranging from ($5.33) to ($4.42). argenx reported earnings of $1.98 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 342.9%. The business is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that argenx will report full year earnings of ($19.44) per share for the current fiscal year, with EPS estimates ranging from ($21.02) to ($17.57). For the next fiscal year, analysts anticipate that the business will report earnings of ($17.47) per share, with EPS estimates ranging from ($21.73) to ($10.95). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for argenx.

argenx (NASDAQ:ARGXGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($4.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.08) by $0.72. argenx had a negative net margin of 147.47% and a negative return on equity of 32.54%. During the same period in the prior year, the company posted ($0.81) EPS.

ARGX has been the topic of several research reports. Morgan Stanley upgraded shares of argenx from an “equal weight” rating to an “overweight” rating and set a $375.00 price objective on the stock in a report on Tuesday, May 3rd. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “hold” rating to a “buy” rating in a research report on Friday, May 13th. JPMorgan Chase & Co. increased their price target on shares of argenx from €350.00 ($372.34) to €370.00 ($393.62) and gave the company an “overweight” rating in a research report on Friday, May 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of argenx in a report on Friday, March 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, argenx presently has a consensus rating of “Buy” and a consensus target price of $360.94.

Shares of argenx stock traded up $3.30 during trading on Wednesday, reaching $316.78. 119,301 shares of the company traded hands, compared to its average volume of 270,229. argenx has a 1-year low of $249.50 and a 1-year high of $356.78. The company has a 50 day moving average price of $310.59 and a 200-day moving average price of $301.15. The firm has a market capitalization of $16.99 billion, a PE ratio of -27.45 and a beta of 1.11.

Hedge funds and other institutional investors have recently modified their holdings of the business. Jennison Associates LLC grew its holdings in shares of argenx by 23.4% in the first quarter. Jennison Associates LLC now owns 1,017,415 shares of the company’s stock worth $320,801,000 after purchasing an additional 192,844 shares during the last quarter. Bellevue Group AG grew its holdings in shares of argenx by 1.3% in the fourth quarter. Bellevue Group AG now owns 997,038 shares of the company’s stock worth $349,153,000 after purchasing an additional 13,100 shares during the last quarter. BlackRock Inc. grew its holdings in shares of argenx by 17.3% in the third quarter. BlackRock Inc. now owns 761,983 shares of the company’s stock worth $230,118,000 after purchasing an additional 112,106 shares during the last quarter. Capital World Investors grew its holdings in shares of argenx by 12.0% in the first quarter. Capital World Investors now owns 739,392 shares of the company’s stock worth $233,138,000 after purchasing an additional 79,119 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of argenx by 19.8% in the third quarter. Wellington Management Group LLP now owns 668,696 shares of the company’s stock worth $201,945,000 after purchasing an additional 110,349 shares during the last quarter. Institutional investors and hedge funds own 58.76% of the company’s stock.

argenx Company Profile (Get Rating)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

Featured Stories

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.